Lamivudina Aurobindo (Lamivudine)

Lamivudine is a nucleoside analogue that is phosphorylated inside cells to its active triphosphate form. It competes with natural nucleotides for incorporation by HIV reverse transcriptase and hepatitis B polymerase, causing premature termination of the viral DNA chain and thereby inhibiting viral replication.

The dose of lamivudine is set by the prescribing clinician based on current treatment guidelines, the specific indication, patient weight, renal and hepatic function, and any concomitant medications. Dosage adjustments may be required for patients with impaired kidney function.

Safety data for lamivudine in pregnancy and lactation are limited. It may be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should assess the risk‑benefit profile and follow local regulatory recommendations.

To request Lamivudina Aurobindo, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the NRTI class and is often combined with other agents such as tenofovir or efavirenz. Compared with some NRTIs, lamivudine has a favorable safety profile and low renal toxicity, but resistance can develop if used as monotherapy. Combination regimens are preferred for optimal viral suppression.

Lamivudina Aurobindo should be stored at temperatures below 25 °C, in its original packaging, protected from moisture, direct sunlight and excessive heat. Keeping the product in a dry, controlled environment helps maintain its potency throughout the shelf‑life.

Lamivudina Aurobindo is administered orally, usually as a tablet or capsule, with or without food. The exact method of intake should follow the prescribing information provided by the healthcare professional.

Serious adverse events linked to lamivudine include lactic acidosis, severe hepatotoxicity, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored for unexplained fatigue, abdominal pain, jaundice, or skin reactions, and medical attention sought promptly if these occur.

Lamivudine is contraindicated in individuals with known hypersensitivity to the drug or any of its components. Caution is advised for patients with severe renal impairment, significant hepatic disease, or those receiving contraindicated medications such as didanosine or stavudine.